A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet

NCT07184086 · Recruiting

Last updated 2026-05-28

This study is testing how weight loss from two medications, cagrilintide and semaglutide, affects metabolism in adults with obesity compared to weight loss from diet alone.

Status Recruiting Currently enrolling participants.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 80 people Planned (estimated).

Who can join Ages 18–65 · all sexes

Timeline Started 2025-09 · est. completion 2027-10

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT07184086 ↗

Description as written by the study sponsor.

In this study we will be looking into how CagriSema influences metabolism (the process by which food is used to supply energy for the body) compared to a diet. CagriSema is a new investigational medicine. CagriSema cannot yet be prescribed by doctors but has previously been tested in humans. The study is split into 2 parts. In the first part of the study, participants will either get CagriSema or a weight loss diet (calorie reduced). In the second part of the study,all participants will get CagriSema. Which treatment participants get in the first part of the study is decided by chance. Like all medicines, the study medicine may have side effects. The study will last for about 1.5 years.

Treatments tested

CagriSema (Cagrilintide B + semaglutide I) Drug

Cagrilintide and semaglutide will be administered subcutaneously.
Low Energy Diet Behavioral

Participants will receive dietary intervention as per diet intervention manual.

Main thing measured	Change in sleeping metabolic rate (SMR)
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	semaglutide, cagrilintide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07184086 ↗